NCT05620160View on ClinicalTrials.gov

Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

1,359

Participants

Timeline

Start Date

November 12, 2022

Primary Completion Date

January 19, 2023

Study Completion Date

March 28, 2023

Conditions
Mild to Moderate COVID-19
Interventions
DRUG

RAY1216

RAY1216（tablet）

DRUG

Placebo

placebo （tablet）

Trial Locations (1)

Unknown

The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY